Eledon Pharmaceuticals, Inc. (ELDN) |
|
2.36 -0.21 (-8.17%)
|
03-24 16:00 |
|
Open: |
2.48 |
Pre. Close: |
2.57 |
|
High:
|
2.58 |
Low:
|
2.2913 |
|
Volume:
|
15,726 |
Market Cap:
|
32(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:25:36 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 3.18 One year: 3.72 |
| Support: |
Support1: 2.21 Support2: 1.89 |
| Resistance: |
Resistance1: 2.73 Resistance2: 3.18 |
| Pivot: |
2.28  |
| Moving Average: |
MA(5): 2.41  MA(20): 2.3
MA(100): 2.59 MA(250): 2.86 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 76.9 %D(3): 72.2 |
| RSI: |
RSI(14): 48.1 |
| 52-week: |
High: 4.13 Low: 1.89 |
| Average Vol(K): |
3-Month: 22 (K) 10-Days: 38 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELDN ] has closed below upper band by 37.6%. Bollinger Bands are 0.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.58 - 2.6 |
2.6 - 2.61 |
|
Low:
|
2.26 - 2.28 |
2.28 - 2.29 |
|
Close:
|
2.34 - 2.36 |
2.36 - 2.38 |
|
Company Description |
|
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. |
Headline News |
Thu, 23 Mar 2023
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating ... - The Bakersfield Californian
Tue, 07 Mar 2023
Fitness Mogul Augie Nieto’s Fight Against ALS Lives On - Orange County Business Journal
Mon, 27 Feb 2023
Ameren Missouri Announces Pricing Of First Mortgage Bonds Due In ... - Kalkine Media
Wed, 08 Feb 2023
Does Eledon Pharmaceuticals Inc (ELDN) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver
Mon, 09 Jan 2023
eGenesis and Eledon Pharmaceuticals Announce Collaboration for ... - GlobeNewswire
Thu, 05 Jan 2023
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
14 (M) |
| Shares Float |
10 (M) |
|
% Held by Insiders
|
10 (%) |
|
% Held by Institutions
|
48.6 (%) |
|
Shares Short
|
17 (K) |
|
Shares Short P.Month
|
17 (K) |
Stock Financials |
|
EPS
|
-2.8 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
10.26 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-15 |
|
Return on Equity (ttm)
|
-24.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-28 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-0.85 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.23 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.16 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-10-04 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
